{"nctId":"NCT00996580","briefTitle":"A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy","startDateStruct":{"date":"2009-10"},"conditions":["Pregnancy Prevention"],"count":3597,"armGroups":[{"label":"DR-103","type":"EXPERIMENTAL","interventionNames":["Drug: DR-103"]}],"interventions":[{"name":"DR-103","otherNames":["levonorgestrel/ethinyl estradiol","Quartette®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Sexually active at risk for pregnancy\n* Agreement to use study OC therapy as their only method of birth control during the study\n* history of regular spontaneous menstrual cycles or withdrawal bleeding episodes\n* Others as dictated by FDA-approved protocol\n\nExclusion Criteria:\n\n* Any contraindication to the use of oral contraceptives\n* Pregnancy or plans to become pregnant in the next 14 months\n* Smoker and age ≥ 35 years\n* Others as dictated by FDA-approved protocol","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or \\> 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.\n\nThe PI is defined as number of contraceptive failures per 100 women-years of exposure:\n\n(100)\\*(total number of pregnancies)\\*(4)/(total number of 91-day cycles)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.82","spread":null},{"groupId":"OG001","value":"2.46","spread":null},{"groupId":"OG002","value":"4.54","spread":null}]}]}]},{"type":"PRIMARY","title":"Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or \\> 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.\n\nThe PI is defined as number of contraceptive failures per 100 women-years of exposure:\n\n(100)\\*(total number of pregnancies)\\*(4)/(total number of 91-day cycles)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","spread":null},{"groupId":"OG001","value":"2.83","spread":null},{"groupId":"OG002","value":"5.32","spread":null}]}]}]},{"type":"PRIMARY","title":"Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or \\> 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.\n\nThe PI is defined as number of contraceptive failures per 100 women-years of exposure:\n\n(100)\\*(total number of pregnancies)\\*(4)/(total number of 91-day cycles)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":null},{"groupId":"OG001","value":"3.23","spread":null},{"groupId":"OG002","value":"6.04","spread":null}]}]}]},{"type":"SECONDARY","title":"All Users Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight","description":"A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the four 91-day treatment cycles.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0074","spread":null},{"groupId":"OG001","value":"0.0060","spread":null},{"groupId":"OG002","value":"0.0139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0134","spread":null},{"groupId":"OG001","value":"0.0114","spread":null},{"groupId":"OG002","value":"0.0231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0212","spread":null},{"groupId":"OG001","value":"0.0185","spread":null},{"groupId":"OG002","value":"0.0339","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0272","spread":null},{"groupId":"OG001","value":"0.0239","spread":null},{"groupId":"OG002","value":"0.0429","spread":null}]}]}]},{"type":"PRIMARY","title":"All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or \\> 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.\n\nIn order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.\n\nThe PI is defined as number of contraceptive failures per 100 women-years of exposure:\n\n(100)\\*(total number of pregnancies)\\*(13)/(total number of 28-day cycles)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":null},{"groupId":"OG001","value":"2.40","spread":null},{"groupId":"OG002","value":"4.42","spread":null}]}]}]},{"type":"PRIMARY","title":"Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or \\> 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.\n\nIn order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.\n\nThe PI is defined as number of contraceptive failures per 100 women-years of exposure:\n\n(100)\\*(total number of pregnancies)\\*(13)/(total number of 28-day cycles)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.92","spread":null},{"groupId":"OG001","value":"2.55","spread":null},{"groupId":"OG002","value":"4.72","spread":null}]}]}]},{"type":"PRIMARY","title":"Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight","description":"Contraceptive failure is measured by the pregnancy rate calculated using the Pearl Index (PI). PI used all pregnancies, as determined by a positive urine and/or serum pregnancy test, except those for which the date of conception was before starting DR-103 or \\> 7 days after stopping the combination EE/LNG treatment of DR-103. The estimated date of conception and gestational age of the fetus was determined by transvaginal or abdominal ultrasound.\n\nIn order to compare the efficacy of extended treatment with DR-103 to conventional 28-day cyclic oral contraceptive treatment, the 91-day DR-103 treatment cycle was separated into three 28-day cycle-equivalents, derived from the 84-day active combination (EE/LNG) pill period of each 91-day extended cycle.\n\nThe PI is defined as number of contraceptive failures per 100 women-years of exposure:\n\n(100)\\*(total number of pregnancies)\\*(13)/(total number of 28-day cycles)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.07","spread":null},{"groupId":"OG001","value":"2.68","spread":null},{"groupId":"OG002","value":"4.94","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Participants With Treatment-emergent Adverse Events","description":"The on-treatment time frame spanned the time during which study drug was administered until 3 weeks beyond the last study drug date.\n\nRelationship to study drug was assessed by the investigator.\n\nSerious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2605","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1086","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"463","spread":null}]}]}]},{"type":"SECONDARY","title":"Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight","description":"A life table approach was used to estimate the cumulative pregnancy rate on a cycle-by-cycle basis for each of the four 91-day treatment cycles.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0080","spread":null},{"groupId":"OG001","value":"0.0062","spread":null},{"groupId":"OG002","value":"0.0164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0134","spread":null},{"groupId":"OG001","value":"0.0116","spread":null},{"groupId":"OG002","value":"0.0215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0236","spread":null},{"groupId":"OG001","value":"0.0203","spread":null},{"groupId":"OG002","value":"0.0392","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0291","spread":null},{"groupId":"OG001","value":"0.0256","spread":null},{"groupId":"OG002","value":"0.0457","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":3597},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Sinusitis","Nausea"]}}}